Transcription of Under ASC 605 - Deloitte
{{id}} {{{paragraph}}}
Example: air traffic controller
Under ASC 605 - Deloitte
Life sciences Accounting and Financial Reporting Update . Interpretive Guidance on Revenue Recognition Under ASC 605. March 2017. Revenue Recognition Introduction Many transactions in the life sciences industry must be carefully analyzed for revenue recognition purposes. Revenue recognition topics that are particularly relevant to life sciences entities include the SAB Topic 131 requirements ( , sales price is fixed or determinable, collectibility is reasonably assured); the accounting for multiple elements; the ability to estimate returns; and the accounting for discounts, rebates, and incentives. Further, biotech and pharmaceutical firms may sometimes encounter complexities related to the milestone method of accounting, the proportional performance method of revenue recognition, principal-agent considerations, license fees, contingent revenue, and up-front payments.
Mar 03, 2016 · (R&D) services for a pharmaceutical company under the arrangement). The sections below discuss (1) guidance on some of the revenue recognition topics frequently encountered by life sciences entities, (2) SEC comment letter themes related to these topics,
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: